Cerevel Launches With Pfizer's Early CNS Assets And $350m From Bain Capital

Pfizer ended its early neuroscience R&D work earlier this year, but will retain a 25% stake in the start-up, which may begin a Phase III Parkinson's disease study in 2019. This is the second time Bain has financed a Pfizer spin-out.